Comparative therapeutic efficacy of a novel lyophilized amphotericin B lecithin-based oil-water microemulsion and deoxycholate-amphotericin B in immunocompetent and neutropenic mice infected with Candida albicans

European Journal of Pharmaceutical Sciences

Volumn 22, Issue 5, 2004, Pages 451-458

  Brime, Begoña ^a   Molero, Gloria ^a   Frutos, Paloma ^a   Frutos, Gloria ^b  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Amphotericin B; Efficacy; Microemulsions; Mycosis; Neutropenic

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; PHOSPHATIDYLCHOLINE; WATER OIL CREAM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; FREEZE DRYING; FUNGUS; IMMUNOCOMPETENCE; KAPLAN MEIER METHOD; MALE; MAXIMUM TOLERATED DOSE; MICROEMULSION; MORTALITY; MOUSE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; RANK SUM TEST; STATISTICAL ANALYSIS; SURVIVAL TIME;

AMPHOTERICIN B; ANIMALS; CANDIDIASIS; CHEMISTRY, PHARMACEUTICAL; DEOXYCHOLIC ACID; EMULSIONS; FREEZE DRYING; IMMUNOCOMPETENCE; MALE; MICE; NEUTROPENIA; PHOSPHATIDYLCHOLINES;

EID: 3242734589     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2004.04.008     Document Type: Article

References (23)

1. Adler-Moore J.P., Proffitt R.T. Development, characterization, efficacy, and mode of action of Ambisome, a unilamellar liposomal formulation of Amphotericin B. J. Lipos. Res. 3:1993;429-450
2. Bodey G., Bueltmann B., Duguid W., Gibbs D., Hanak H., Hotchi M. Fungal infections in cancer patients: an international autopsy survey. Eur. J. Clin. Microbiol. Infect. Dis. 11:1992;99-109
3. Brajtburg J., Powderly W.G., Kobayashi G.S., Medoff G. Amphotericin B: current understanding of mechanisms of action. Antimicrob. Agents Chemother. 34:1990;183-188
4. Brime B., Frutos P., Bringas P., Nieto A., Ballesteros M.P., Frutos G. Comparative pharmacokinetics and safety of a novel lyophilized Amphotericin B lecithin-based oil-water microemulsion and Amphotericin B-deoxycholate in animal models. J. Antimicrob. Chemother. 52:2003;103-109
5. Brime B., Moreno M.A., Frutos G., Ballesteros M.P., Frutos P. Amphotericin B in oil-water lecithin-based microemulsions: formulation and toxicity evaluation. J. Pharm. Sci. 91(4):2002;1178-1185
6. De Pauw B.E. Treatment of documented and suspected neutropenia-associated invasive fungal infections. J. Chemother. 1(1):2001;181-192
7. Englehard D., Marks M.I., Good R.A. Infection in bone marrow transplants recipients. J. Pediatr. 108:1986;335-346
8. Garcia A., Adler-Moore J.P., Proffitt R.T. Single-dose Ambisome (liposomal Amphotericin B) as prophylaxis for murine systemic candidiasis and histoplasmosis. Antimicrob. Agents Chemother. 44(9):2000;2327-2332
9. Grit M., Zuidam N.J., Underberg W.J., Crommelin D.J. Hydrolysis of partially saturated egg phosphatidilcholine in aqueous liposome dispersions and the effect of cholesterol incorporation on hydrolysis kinetics. J. Pharm. Pharmacol. 45:1993;490-495
10. Guo L.S., Working P.K. Complexes of Amphotericin B and cholesteryl sulfate. J. Lipos. Res. 3:1993;473-490
11. Heinemann V., Bosse D., Jehn U. Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients. Antimicrob. Agents Chemother. 41:1997;1275-1280
12. Janoff A.S., Perkins W.R., Saletan S.L., Swenson C.E. Amphotericin B lipid complex (ABLC): a molecular rationale for the attenuation of Amphotericin B related toxicities. J. Lipos. Res. 3:1993;451-471
13. Moreno M.A., Ballesteros M.P., Frutos P. Lecithin-based oil-in-water microemulsions for parenteral use: pseudoternary phase diagrams, characterization, and toxicity studies. J. Pharm. Sci. 92(7):2003;1428-1437
14. Moreno M.A., Frutos P., Ballesteros M.P. Lyophilized lecithin-based oil-water microemulsions as a new and low toxic delivery system for Amphotericin B. Pharm. Res. 18(3):2001;344-351
15. Papadimitriou J.M., Ashman R.B. The pathogenesis of acute systemic candidiasis in a susceptible inbred mouse strain. J. Pathol. 150:1986;257-265
16. Pfaller M.A., Jones R.N., Doern G.V., Sader H.S., Hollis R.J., Messe S.A. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. The SENTRY participant group. J. Clin. Microbiol. 36:1998;1886-1889
17. Reynolds, J.E.F, Parfitt, K., Parsons, A.V., Sweetman, S.C., 1996. Amphotericin, In: Martindale (Ed.), The Extra Phrarmacopoeia, 31st ed. Royal Pharmaceutical Society, London, pp. 398-402.
18. Richardson S.E., Bannatyne R.M., Summerbell R.C., Milliken J., Gold R., Weitzman S.S. Disseminated fusarial infection in the immunocompromised host. Rev. Infect. Dis. 10:1988;1171-1181
19. Robinson R.F., Nahata M.C. A comparative review of conventional and lipid formulations of AmB. J. Clin. Pharm. Ther. 24:1999;249-257
20. Ryley J.F., McGregor S., Lister S.C., Jackson K.P. Kidney function in experimental systemic candidiosis of mice. Mycoses. 31:1988;203-207
21. Thaler M., Pastakia B., Shawker T.H., O'Leary T., Pizzo P.A. Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. Ann. Intern. Med. 108:1988;88-100
22. Van Burik J.A., Myerson D., Schreckhise R.W., Bowden R.A. Panfungal PCR assay for detection of fungal infection in human blood specimens. J. Clin. Microbiol. 36:1998;1169-1175
23. Wong-Beringer A., Jacobs R.A., Guglielmo B.J. Lipid formulations of Amphotericin B: clinical efficacy and toxicities. Clin. Infect. Dis. 27:1998;603-618